- Home
- ONIT vs CRVS Comparison
ONIT vs CRVS Comparison
Compare ONIT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONIT
- CRVS
- Stock Information
- Founded
- ONIT 1988
- CRVS 2014
- Country
- ONIT United States
- CRVS United States
- Employees
- ONIT N/A
- CRVS N/A
- Industry
- ONIT
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- ONIT
- CRVS Health Care
- Exchange
- ONIT NYSE
- CRVS Nasdaq
- Market Cap
- ONIT N/A
- CRVS 257.0M
- IPO Year
- ONIT 1996
- CRVS 2016
- Fundamental
- Price
- ONIT $32.32
- CRVS $3.18
- Analyst Decision
- ONIT Buy
- CRVS Strong Buy
- Analyst Count
- ONIT 1
- CRVS 5
- Target Price
- ONIT $45.00
- CRVS $12.63
- AVG Volume (30 Days)
- ONIT 39.4K
- CRVS 697.0K
- Earning Date
- ONIT 05-01-2025
- CRVS 03-25-2025
- Dividend Yield
- ONIT N/A
- CRVS N/A
- EPS Growth
- ONIT N/A
- CRVS N/A
- EPS
- ONIT 4.13
- CRVS N/A
- Revenue
- ONIT $976,000,000.00
- CRVS N/A
- Revenue This Year
- ONIT $8.40
- CRVS N/A
- Revenue Next Year
- ONIT $13.89
- CRVS N/A
- P/E Ratio
- ONIT $7.89
- CRVS N/A
- Revenue Growth
- ONIT N/A
- CRVS N/A
- 52 Week Low
- ONIT $22.40
- CRVS $1.30
- 52 Week High
- ONIT $41.27
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- ONIT 51.18
- CRVS 28.07
- Support Level
- ONIT $32.21
- CRVS $3.20
- Resistance Level
- ONIT $35.71
- CRVS $3.45
- Average True Range (ATR)
- ONIT 1.41
- CRVS 0.38
- MACD
- ONIT 0.25
- CRVS -0.11
- Stochastic Oscillator
- ONIT 48.40
- CRVS 5.36
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).